Alcon Laboratories, Inc.

Alcon, Inc.

Alcon Research, Ltd.

Arrowhead Pharmaceuticals, Inc.

Alcon Manufacturing, Ltd.

Alcon Universal Ltd.

Other

Alcon Pharmaceuticals Ltd.

Arrowhead Research Corporation

Kyowa Hakko Kogyo Co., Ltd.

Kalypsys, Inc.

Pruvyc Pharma, LLC

John M. Yanni

Steven T. Miller

Ltd. Alcon Manufacturing

John M Yanni

Daniel A Gamache

Steven T Miller

Jon E Chatterton

Gustav Graff

Gerald D Cagle

David W Stroman

Robert L Abshire

Mark R Hellberg

Stella M Robertson

Diane Michelle Senchyna

Linda L Clark

Celeste H McLean

Peter G Klimko

Billie M York

Haresh G Bhagat

Tadayuki Saito

L Wayne Schneider

Hitoshi Tanaka

Shigetoshi Okumura

Terri Pasquine

Lori K Weimer

Mutlu Karakelle

Steven P Govek

Raymond E Conrow

Stewart Alwyn Noble

Eiji Hayakawa

Michael A Kapin

Andrew Shiau

John W Sheets, Jr

Mark T Dupriest

David J Thomas

Masashi Nakakura

Eric C Carlson

Timothy L Kessler

Clay Beauregard

John E Chatterton

Zhongyou Wei

David W Stromann

Methods for treating pruritis in humans and animals using topically administrable compositions containing olopatadine are disclosed. The compositions quickly relieve itchy skin.

Method for treating pruritus

RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.

RNAi-mediated inhibition of histamine receptor H1-related conditions

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders

RNA interference is provided for inhibition of tumor necrosis factor &#x3b1; (TNF&#x3b1;) by silencing TNF&#x3b1; cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF&#x3b1; converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF&#x3b1; targets, in particular, is useful for treating patients having a TNF&#x3b1;-related condition or at risk of developing a TNF&#x3b1;-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.

RNAi-mediated inhibition of tumor necrosis factor &#x3b1;-related conditions

RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.

Compositions containing moxifloxacin for treating otic infections

Method of treating otic infections with moxifloxacin compositions

The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

Heteroarylalkoxy-substituted quinolone inhibitors of PDE4

Growing community of inventors

Burleson, TX, United States of America

John M Yanni